How Our Mytide Investment Supports the Peptides Ecosystem
Peptides are a promising therapeutic modality in that they are small and specific in their targeting, while being relatively inexpensive to manufacture. Insulin is perhaps the best-known therapeutic peptide, but since 2000 33 non-insulin peptide therapeutics have been approved, spanning treatments for HIV, chronic pain, metabolic disease, cancer, cardiovascular disease, and more. Improvements in production, […]
Mytide Therapeutics Raises $7 Million Series A Round to Transform Peptide Manufacturing with Machine Learning
Biotech ecosystem company Alloy Therapeutics leads the round, joined by Uncommon Denominator and Mytide founders BOSTON, March 8th, 2021–Mytide Therapeutics, a company transforming peptide manufacturing with predictive analytics and machine learning, has raised $7 million in Series A financing. The round was led by Alloy Therapeutics, a biotechnology ecosystem company, and was joined by Uncommon […]
Alloy Therapeutics Acquires deepCDR Biologics to Bring Bioinformatics and Machine Learning to its Antibody Discovery Offering
The Basel, Switzerland-based deepCDR team and technology will strengthen Alloy’s antibody discovery platform and services for its ecosystem of 100+ global partners Boston, MA, USA and Basel, Switzerland, December 9th, 2021 – Alloy Therapeutics, a biotechnology ecosystem company, announced it has acquired deepCDR Biologics, a Basel, Switzerland-based developer of deep learning technology for antibody discovery and […]
Alloy Therapeutics and Echo Investment Capital Create Wheeler Bio to Accelerate the Development of New Antibody Therapeutics
BOSTON, MA & OKLAHOMA CITY, OK, July 21st, 2021 – Alloy Therapeutics and Echo Investment Capital today announced the formation of Wheeler Bio, a new biomanufacturing company built to accelerate the translation of therapeutic innovation into clinical impact. Wheeler’s comprehensive discovery-to-IND programs are designed to provide emerging biopharma companies a faster and more predictable path […]
Vernal Biosciences Launches to Democratize Access to High Quality mRNA Manufacturing
Seed Financing Will Scale Company’s Technology and Business Operations to Serve Clients of All Stages BURLINGTON, VT, July 12th, 2021 – Vernal Biosciences, Inc., a manufacturer of high purity mRNA for research and clinical use, today announced the closing of a seed round of financing. Alloy Therapeutics led the round and was joined by the […]
